The Effect of Annona Muricata Leaves Towards Blood Levels of Cxcl9 and Lymphoblast (Study in Cerebral Malaria Phase of Swiss Mice)

Mohamed M.Y. Gadalla, Edi Dharmana, Kiss Jamiatun, Budi Laksono


Cerebral malaria (CM) forms part of the spectrum of severe malaria, with a case fatality rate ranging from 15% in adults in southeast Asia to 8.5% in children in Africa. A.Muricata was used to cure Malaria in traditional medicine. The research will examine the effect of it in the chemokine (C-X-C motif) receptor 3 (CXCR3) binding chemokines, including chemokine (C-X-C motif) ligand 4 (CXCL4), CXCL9. The intervented mice group were infected then the its spleen were cultured , incubation 72 hours and then analyzed the result. The CXCL9 level of PbA-infected mice treated with A. muricata are lower than group of infected mice without treatment. Lymphoblast level of PbA-infected mice treated with A. Muricata are higher than group of infected mice without treatment. A. Muricata treatment cure in the CM in the mice and may be a potential treatment in human CM.

Cerebral malaria (CM) adalah keadaan infeksi malaria yang berat dengan tingkat kefatalan dari 15% di Asia tenggara dan 8% di Afrika. A. Muricata secara tradisional dipakai mengobati CM. Riset ini meneliti pengaruh A. Muricata pada ikatan chemokine (C-X-C motif) reseptor 3 (CXCR3)termasuk chemokine (C-X-C motif) ligand 4 (CXCL4) dan CXCL9. Kelompok mice intervensi diinfeksi dan limfanya di culture dalam inkubator 72 jam untuk dianalisis. Kadar PbA CXCL9 pada mencit intervensi yang diberi A. Muricata lebih rendah dari pada kontrol. Kadar PbA limfoblast intervensi lebihtinggi dari pada kontrol. A. Muricata memperbaiki CM pada mencit dan berpotensi sebagai pengobat pada CM manusia.


CXCL9; PbA-infected mice; A. muricata; Lymphoblast level.

Full Text:



Armah HB, et al. (2007) Cerebrospinal fluid and serum biomarkers of cerebral malaria mortality in Ghanaian children. Malar J 6:147 (abstr).

Beare NA, Lewallen S, Taylor TE, Molyneux ME. (2011).Redefining cerebral malaria by including malaria retinopathy. Future Microbiol. 6, pp.349355

Dondorp A, Nosten F, Stepniewska K, Day N, White N. (2005). Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 366, pp.717725

Dondorp AM, Fanello CI, Hendriksen IC et al. (2010).Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 376, pp.16471657

Dorovini-Zis K, Schmidt K, Huynh H et al. (2011).The neuropathology of fatal cerebral malaria in malawian children. Am. J. Pathol. 178, pp.21462158

Grau, G. E., and J. N. Lou. (1995). Experimental cerebral malaria: possible new mechanisms in the TNF-induced microvascular pathology. Soz. Praventivmed. 40, pp.50-57.

Hansen, D. S., N. J. Bernard, C. Q. Nie, and L. Schofield. (2007). NK cells stimulate recruitment of CXCR3+ T cells to the brain during Plasmodium berghei-mediated cerebral malaria. J. Immunol. 178, pp.5779-5788.

Idro R, Jenkins NE, Newton CR. (2005).Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet Neurol. 4, pp.827840

John CC, Opika-Opoka R, Byarugaba J, Idro R, Boivin MJ. (2006). Low levels of RANTES are associated with mortality in children with cerebral malaria. J Infect Dis 194, pp.837845.

Luster, A. D., R. Alon, and U. H. von Andrian. (2005). Immune cell migration in inflammation: present and future therapeutic targets. Nat. Immunol. 6, pp.1182-1190.

MacPherson GG, Warrell MJ, White NJ, Looareesuwan S, Warrell DA. (1985). Human cerebral malaria. A quantitative ultrastructural analysis of parasitized erythrocyte sequestration. Am. J. Pathol. 119, pp.385401

Maude RJ, Beare NA, Abu Sayeed A et al. (2009).The spectrum of retinopathy in adults with Plasmodium falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 103, pp.665671

World Health Organization. (2000). Severe falciparum malaria. Communicable Diseases Cluster. Trans. R. Soc. Trop. Med. Hyg. 94(Suppl. 1),S1S90

WHO. (2010).Guidelines for the Treatment of Malaria (2nd Edition). The WHO, Geneva, Switzerland



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.